autoimmune hepatitis
Hepatocellular injury with autoantibodies (ANA, ASMA, anti-LKM1), raised IgG and interface hepatitis on biopsy. Can present as chronic hepatitis, cirrhosis, or acute severe hepatitis mimicking DILI. Biopsy before treatment unless too unstable. Induction: prednisone + azathioprine, or budesonide + azathioprine if no cirrhosis and not acute severe. Maintenance azathioprine; withdrawal only after ≥2 years of normal ALT and IgG, and most relapse. Always exclude Wilson disease and DILI.
diagnosis
- Serology: ANA, ASMA (type 1); anti-LKM1 (type 2, mostly children); anti-SLA (severe disease). ~20% seronegative.
- IgG raised in most; normal IgG doesn’t exclude.
- Biopsy — interface hepatitis, plasma cells, rosettes; stages fibrosis and detects overlap. Simplified IAIHG score ≥7 = definite AIH.
- Exclude: viral hepatitis, DILI (nitrofurantoin, minocycline, statins, checkpoint inhibitors can mimic AIH), Wilson disease (ANA and IgG can be positive — check ceruloplasmin), MASLD.
- Associated autoimmune disease: thyroid, coeliac, type 1 diabetes, IBD.
treatment
| situation | induction |
|---|---|
| no cirrhosis, not acute severe | budesonide 3 mg TID + azathioprine, or prednisone + azathioprine |
| cirrhosis or acute severe AIH | prednisone + azathioprine (budesonide: portosystemic shunting → systemic exposure) |
- Prednisone 40–60 mg (or 0.5–1 mg/kg) → taper as ALT falls. Azathioprine added after ~2 weeks once bilirubin falling (and TPMT checked), titrated to 1–2 mg/kg.
- TPMT before azathioprine.
- Goal: biochemical remission — normal ALT/AST and IgG.
- Second-line (azathioprine intolerance or non-response): mycophenolate mofetil; then tacrolimus.
- Maintenance: azathioprine (or low-dose steroid if azathioprine not tolerated); continue through pregnancy.
- Withdrawal — consider only after ≥2 years of normal ALT and IgG; biopsy first; relapse is common (most), so monitor closely.
Jaundice, INR 1.5–2, no encephalopathy. Start prednis(ol)one alone (0.5–1 mg/kg) early and refer to a transplant centre; no improvement within ~1–2 weeks → transplant evaluation. Acute liver failure (encephalopathy) → transplant listing rather than escalating steroids.
overlap
- AIH–PBC: AMA+, cholestatic + hepatitic features, interface hepatitis on biopsy → UDCA + immunosuppression.
- AIH–PSC: cholangiographic PSC + interface hepatitis, often younger, with IBD → treat AIH component per AIH guidance.
- Biopsy is needed to call an overlap. PBC and PSC → primary biliary and sclerosing cholangitis.
long-term
- Cirrhosis → HCC surveillance (hepatocellular carcinoma), varices (cirrhosis).
- Steroids → bone protection, DEXA; vaccinate before immunosuppression.
Prepared 2026-10-28. Not yet verified — check every number against the sources.